Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for serious musculoskeletal diseases, including osteoporosis and degenerative disc disease. By utilizing advanced drug development techniques, Angitia aims to provide effective treatments that address significant unmet medical needs in this patient population.
Funding
$290M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Musculoskeletal diseases like osteoporosis and degenerative disc disease represent significant unmet medical needs, often leading to pain, disability, and reduced quality of life. Current treatments may not fully address the underlying causes or provide sufficient long-term relief for these conditions.
Solution
Angitia Biopharmaceuticals is developing novel therapeutics to address serious musculoskeletal diseases, including osteoporosis, degenerative disc disease, osteogenesis imperfecta, bone metastasis, nonunion, osteoarthritis and muscle disorders. The company utilizes advanced drug development techniques to create therapies that target the underlying mechanisms of these diseases. Angitia's lead candidate, AGA2118, is currently in Phase 2 clinical trials for the treatment of osteoporosis.
Target Audience
The primary target audience includes patients suffering from musculoskeletal diseases such as osteoporosis, degenerative disc disease, osteogenesis imperfecta, bone metastasis, nonunion, osteoarthritis and muscle disorders.
Features
- Focus on therapeutics for musculoskeletal diseases, including osteoporosis and degenerative disc disease.
- AGA2118: A novel therapeutic currently in Phase 2 clinical trials for osteoporosis.
- Targets underlying mechanisms of musculoskeletal diseases.
- Dedicated to bringing innovative therapies to patients in need.